Flowchart of patient follow-up
Screening | Inclusion D0 | Study period | Death/30 days | Follow-up 6 months | |
Baseline information | |||||
Demographic data and history | √ | √ | |||
Inclusion and exclusion criteria | √ | ||||
Written informed consent | √ | ||||
Diagnosis and focus of infection | √ | √ | √ | ||
Vital signs | √ | ||||
APACHEII/SOFA | √ | √D1, 3, 7 | |||
Efficacy observation | |||||
Cardiac function assessment (CI, LVEF) | √ | √ | √D1, 3, 5, 7, 10, 14 | √ | √ |
ECMO intervention | √ | ||||
Treatment with vesopressor | √ | √ | √ | ||
Mechanical ventilation | √ | √ | |||
CRRT implication | √ | √ | |||
Laboratory tests | √ | √ | √D1, 3, 5, 7 | ||
Safety observation | |||||
Complications of ECMO | √ | ||||
Adverse event | √ | ||||
Additional observation | |||||
ICU and hospital LOS | √ | ||||
Alive or dead status | √ | √ | |||
Life quality (EQ-5D score) | √ |
APACHEII, Acute Physiology and Chronic Health Evaluation II; CI, cardiac index; CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation; LOS, length of stay; SOFA, Sequential Organ Failure Assessment.